Search
for
Sort by
Research
960-990 / 1000+ results
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Patient Considerations when Using Ritlecitinib for Alopecia Areata in Adolescents: Guidance for the Clinicians
Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
research The efficacy and safety of tofacitinib in patients with alopecia totalis
Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
research 전립선비대증의 치료로 Tamsulosin, Finasteride 병합요법시 투여 방법 및 증상호전에 따른 약물 순응도의 차이 분석
For better medication adherence in benign prostatic hyperplasia treatment, tamsulosin and finasteride should be packaged together and taken at the same time.
research New Finasteride Trial Results Aim To Curb Controversy
research Beyond Hair Regrowth: Interpreting the Psychosocial Impact of Ritlecitinib in Alopecia Areata
Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.
research A New Strategy for Consumption of Functional Lipids from Ericerus pela (Chavannes): Study on Microcapsules and Effervescent Tablets Containing Insect Wax–Derived Policosanol
Microcapsules and effervescent tablets make insect lipids easier to consume.
research Ethosomes: An Exciting and Promising Alcoholic Carrier System for Treating Androgenic Alopecia
Ethosomes are a promising method for treating hair loss by delivering drugs directly to the scalp.
research Evaluating the combined efficacy of oral isotretinoin and topical tacrolimus versus oral finasteride and topical tacrolimus in frontal fibrosing alopecia—A randomized controlled trial
Isotretinoin with tacrolimus may be more effective short-term for treating frontal fibrosing alopecia than finasteride with tacrolimus.
research Eclipta alba, An Antioxidant-Rich Memory Enhancer: In-Silicoand In-Vivo Evidence with Specific Insight into Alzheimer’s Disease
Eclipta alba may improve memory and help treat Alzheimer's disease.
research The Double-Edged Sword of Epidermal Growth Factor Receptor Inhibitor: Rash as Toxicity and Prognostic Marker
A 50-year-old man undergoing treatment with the epidermal growth factor receptor inhibitor (EGFRI) lapatinib for stage 2 breast carcinoma developed a papulopustular rash, a common side effect of EGFRIs, affecting 50-100% of patients. This rash, part of the 'PRIDE' complex, includes various cutaneous adverse effects such as xerosis and eczema. The patient was treated with doxycycline and hydrocortisone cream, showing significant improvement within a week. Acneiform eruptions, which lack comedones, may serve as a potential marker for therapeutic response to EGFRI drugs, although evidence is inconsistent. The rash typically appears within 1-2 weeks of therapy, peaks at 3-4 weeks, and subsides gradually. Patients are advised on sun protection and gentle skincare to manage symptoms.
research Acne exacerbation after tofacitinib treatment for alopecia areata
Tofacitinib treatment for hair loss may worsen acne.
research Alopecia areata after mogamulizumab treatment
Mogamulizumab can cause hair loss and skin rashes.
research Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review includingGRADE assessments
Some medications can reduce excessive hair growth in women, but more research is needed to find the best treatment combinations.
research Modern approach to the treatment of patients with androgen-dependent dermatopathies
Cyproterone acetate improves skin symptoms and quality of life in women with androgen-related issues.
research Ultra-low dose estradiol and dydrogesterone for the treatment of menopausal symptoms in a pooled, multi-ethnic population
The treatment effectively reduces menopausal symptoms and is well tolerated.
research Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
research Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
Apremilast shows promise for several skin conditions but needs more research.
research Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men
Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.
research Oral Tofacitinib for Refractory Lichen Planus Pigmentosus Coexisting with Frontal Fibrosing Alopecia
Tofacitinib significantly improved skin and hair conditions without side effects.
research 565 Cutaneous delivery of LEKTI via an engineered strain of staphylococcus epidermidis for the treatment of netherton syndrome
ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
research Selective Delivery of Tofacitinib Citrate to Hair Follicles Using Lipid-Coated Calcium Carbonate Nanocarrier Controls Chemotherapy-Induced Alopecia Areata
A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
research Cutaneous lupus erythematosus induced by tislelizumab
Tislelizumab can cause cutaneous lupus erythematosus.
research Synthesis and Pharmacological Evaluation of New Progesterone Esters as 5.ALPHA.-Reductase Inhibitors
Smaller substituents at C-17 enhance the inhibitory activity of progesterone derivatives on 5alpha-reductase.
research Transferosomes versus transethosomes for the dermal delivery for minoxidil: Preparation and in vitro/ex vivo appraisal
Minoxidil, a hair loss treatment, works better and has fewer side effects when put into tiny particles called transethosomes, especially those containing oleic acid.
research Baricitinib in Alopecia Areata: Real-Life Changes in Lipid Profile and Hematologic Inflammation Indices at 52 weeks
Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.
research Xiaozhi Yufa decoction ameliorates androgenetic alopecia through inhibition of MAPK signaling and regulation of lipid metabolism
Xiaozhi Yufa decoction may help treat hair loss by improving hair growth and reducing inflammation.
research Les Rencontres d’Experts du Psoriasis : des recommandations pour la pratique quotidienne
Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
research Case Report of a Patient With Psoriasis Vulgaris, Psoriatic Arthritis and Alopecia Universalis Successfully Treated With Tofacitinib and Methotrexate
Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.